8-K: Kineta Inc. to be Delisted from Nasdaq, Trading to Commence on OTC Markets

Kineta, Inc. will be delisted from the Nasdaq Capital Market due to non-compliance with listing rules and will begin trading on the OTC Markets Group platform on September 19, 2024.

Summary

• Kineta, Inc. received a notification from Nasdaq that its request for continued listing was denied due to non-compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1).
• The company did not appeal the decision, leading to the suspension of trading on the Nasdaq Capital Market effective September 19, 2024.
• A Form 25-NSE will be filed with the Securities and Exchange Commission by Nasdaq, and the delisting will become effective 10 days after the filing.
• Kineta's common stock will begin trading on the OTC Markets Group platform on September 19, 2024, under the symbol KA.
• The company will continue to be a reporting company under the Securities Exchange Act of 1934 despite the delisting.

Sentiment

Score: 3

Explanation: The delisting from Nasdaq is a significant negative event, indicating potential financial or operational issues. While the company will continue to trade on the OTC market, this is generally seen as a less desirable outcome.

Positives

• Kineta will continue to be a reporting company under the Securities Exchange Act of 1934.
• The company's stock will continue to be traded on the OTC Markets Group platform.

Negatives

• Kineta's common stock will be delisted from the Nasdaq Capital Market.
• The company failed to meet Nasdaq's listing requirements.
• Trading on Nasdaq will be suspended starting September 19, 2024.

Risks

• The delisting from Nasdaq could negatively impact investor confidence and the company's stock price.
• Trading on the OTC Markets may result in lower liquidity and visibility compared to Nasdaq.
• The company's failure to comply with Nasdaq listing rules raises concerns about its financial health and governance.

Future Outlook

Kineta will continue to operate as a reporting company under the Securities Exchange Act of 1934 and will trade on the OTC Markets Group platform.

Management Comments

• The company did not appeal the determination from Nasdaq.

Industry Context

Delisting from a major exchange like Nasdaq can be a significant setback for a company, often leading to reduced investor confidence and liquidity. Companies that fail to meet listing requirements may face challenges in raising capital and maintaining market visibility. Moving to the OTC market is a common outcome for companies that are delisted from major exchanges.

Comparison to Industry Standards

• Companies like Novan, Inc. and Aeterna Zentaris Inc. have also faced delisting from Nasdaq due to non-compliance with listing rules, highlighting the challenges faced by smaller biotech companies in maintaining compliance.
• The move to the OTC market is a common path for companies that are delisted, with companies like Titan Pharmaceuticals and Delcath Systems having made similar transitions.
• The delisting process and the subsequent move to the OTC market are generally consistent with industry standards for companies that fail to meet exchange listing requirements.

Stakeholder Impact

• Shareholders may experience a decrease in the value of their investment due to the delisting.
• Employees may face uncertainty about the company's future.
• The company's reputation may be negatively impacted.

Next Steps

• Kineta's common stock will begin trading on the OTC Markets Group platform on September 19, 2024.
• A Form 25-NSE will be filed with the SEC by Nasdaq.
• The delisting will become effective 10 days after the Form 25-NSE is filed.

Key Dates

Keywords

delisting, Nasdaq, OTC Markets, listing rules, trading suspension, Form 25-NSE, compliance, Kineta